Now that Vivus ($VVUS) has its approval for the weight-loss drug Qsymia, some contractors are set to reap their own benefits from the product launch. PDI, a contract sales group, expects to gain $57 million from a deal to market the drug, while API maker ScinoPharm is on board to manufacture one of its active ingredients. Release | Report